Latest Insider Transactions at 9 Meters Biopharma, Inc. (NMTR)
This section provides a real-time view of insider transactions for 9 Meters Biopharma, Inc. (NMTR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of 9 METERS BIOPHARMA, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of 9 METERS BIOPHARMA, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 21
2023
|
Bethany Sensenig Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,100
-18.14%
|
$9,100
$1.21 P/Share
|
|
Mar 29
2023
|
Mark A Sirgo Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,885
+8.41%
|
-
|
|
Mar 29
2023
|
Yehuda Michael Rice Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,885
+50.0%
|
-
|
|
Mar 29
2023
|
Lorin K Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,885
+39.41%
|
-
|
|
Mar 29
2023
|
Michael T. Constantino Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,885
+41.95%
|
-
|
|
Mar 29
2023
|
Samantha Ventimiglia Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,885
+50.0%
|
-
|
|
Mar 27
2023
|
Bethany Sensenig Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,177
+50.0%
|
-
|
|
Mar 27
2023
|
John Temperato Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,815
+32.92%
|
-
|
|
Jul 06
2022
|
John Temperato Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
125,000
+8.05%
|
$0
$0.23 P/Share
|
|
Jul 01
2022
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
175,000
+10.74%
|
$0
$0.25 P/Share
|
|
May 23
2022
|
Michael T. Constantino Director |
BUY
Open market or private purchase
|
Direct |
16,000
+20.91%
|
$0
$0.48 P/Share
|
|
May 18
2022
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
106,383
+7.13%
|
$0
$0.47 P/Share
|
|
May 18
2022
|
John Temperato Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+3.7%
|
$0
$0.45 P/Share
|
|
Mar 03
2022
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
86,449
+6.33%
|
$0
$0.58 P/Share
|
|
Mar 03
2022
|
John Temperato Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
100,000
+7.39%
|
$0
$0.56 P/Share
|
|
Dec 02
2021
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
50,000
+3.87%
|
$0
$0.89 P/Share
|
|
Nov 18
2021
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
20,000
+1.65%
|
$20,000
$1.06 P/Share
|
|
Nov 18
2021
|
John Temperato Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+4.16%
|
$50,000
$1.05 P/Share
|
|
Sep 14
2021
|
Edward J Sitar Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+7.17%
|
$15,000
$1.22 P/Share
|
|
Sep 07
2021
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
73,529
+5.9%
|
$73,529
$1.36 P/Share
|
|
Aug 24
2021
|
Michael T. Constantino Director |
BUY
Open market or private purchase
|
Direct |
18,000
+25.67%
|
$18,000
$1.14 P/Share
|
|
Aug 20
2021
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
25,000
+2.22%
|
$25,000
$1.1 P/Share
|
|
Aug 18
2021
|
John Temperato Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+2.22%
|
$25,000
$1.05 P/Share
|
|
Jun 25
2021
|
Orbi Med Israel Gp Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,989,876
-65.12%
|
$15,989,876
$1.21 P/Share
|
|
Jun 24
2021
|
Orbi Med Israel Gp Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
319,255
-1.28%
|
$319,255
$1.38 P/Share
|
|
Jun 23
2021
|
Orbi Med Israel Gp Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
841,650
-3.27%
|
$841,650
$1.36 P/Share
|
|
May 11
2021
|
Orbi Med Israel Gp Ltd. > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
31,944
+0.06%
|
$0
$0.66 P/Share
|
|
Apr 05
2021
|
Edward J Sitar Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+21.8%
|
$50,000
$1.0 P/Share
|
|
Apr 05
2021
|
John Temperato Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
100,000
+8.49%
|
$100,000
$1.0 P/Share
|
|
Apr 05
2021
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
300,000
+21.83%
|
$300,000
$1.0 P/Share
|
|
Dec 15
2020
|
Edward J Sitar Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
61,538
+32.24%
|
$0
$0.65 P/Share
|
|
Dec 15
2020
|
Mark A Sirgo Director |
BUY
Open market or private purchase
|
Direct |
230,769
+22.97%
|
$0
$0.65 P/Share
|
|
Dec 15
2020
|
John Temperato Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
153,846
+13.6%
|
$0
$0.65 P/Share
|
|
Nov 27
2020
|
John Temperato Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
203,667
+19.82%
|
-
|
|
Oct 30
2020
|
John Temperato Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
4,513
+0.72%
|
-
|
|
Oct 30
2020
|
Mark A Sirgo Director |
BUY
Other acquisition or disposition
|
Direct |
4,513
+0.82%
|
-
|
|
Oct 30
2020
|
Nissim Darvish Director |
BUY
Other acquisition or disposition
|
Indirect |
1,943,734
+7.03%
|
-
|
|
Oct 30
2020
|
Orbi Med Israel Gp Ltd. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
1,943,734
+7.03%
|
-
|